ABSTRACT

Introduction

Advanced breast cancer (aBC) remains incurable and the quest for more effective systemic anticancer agents continues. Promising results have led to the FDA approval of three antibody–drug conjugates (ADCs) and two immune checkpoint inhibitors (ICIs) to date for patients with aBC.

Areas covered

With the anticipated emergence of newer ADCs and ICIs for patients with several subtypes of breast cancer, and given their potential synergy, their use in combination is of clinical interest. In this article, we review the use of ADCs and ICIs in patients with breast cancer, assess the scientific rationale for their combination, and provide an overview of ongoing trials and some early efficacy and safety results of such dual therapy.

Expert Opinion

Improvement in the medicinal chemistry of next-generation ADCs, their rational combination with ICIs and other agents, and the development of multiparametric immune biomarkers could help to significantly improve the outlook for patients with refractory aBC.

中文翻译：

---

抗体-药物偶联物、免疫检查点抑制剂及其在乳腺癌治疗中的组合

摘要

介绍

晚期乳腺癌 (aBC) 仍然无法治愈，对更有效的全身性抗癌药物的探索仍在继续。有希望的结果导致 FDA 批准了迄今为止用于 aBC 患者的三种抗体药物偶联物 (ADC) 和两种免疫检查点抑制剂 (ICI)。

涵盖的领域

随着针对几种乳腺癌亚型患者的新型 ADC 和 ICI 的预期出现，并且考虑到它们的潜在协同作用，它们的组合使用具有临床意义。在本文中，我们回顾了 ADC 和 ICI 在乳腺癌患者中的使用，评估了它们组合的科学原理，并概述了正在进行的试验以及这种双重治疗的一些早期疗效和安全性结果。

专家意见

下一代 ADC 药物化学的改进、它们与 ICI 和其他药物的合理组合以及多参数免疫生物标志物的开发有助于显着改善难治性 aBC 患者的前景。